Literature DB >> 26670634

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Ana C Alho1, Haesook T Kim2, Marie J Chammas3, Carol G Reynolds3, Tiago R Matos4, Edouard Forcade4, Jennifer Whangbo4, Sarah Nikiforow4, Corey S Cutler4, John Koreth4, Vincent T Ho4, Philippe Armand4, Joseph H Antin4, Edwin P Alyea4, Joao F Lacerda5, Robert J Soiffer4, Jerome Ritz6.   

Abstract

The development and maintenance of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT) requires the balanced reconstitution of donor-derived CD4 regulatory T cells (CD4Tregs) as well as effector CD4 (conventional CD4 T cells [CD4Tcons]) and CD8 T cells. To characterize the complex mechanisms that lead to unbalanced recovery of these distinct T-cell populations, we studied 107 adult patients who received T-replete stem cell grafts after reduced-intensity conditioning. Immune reconstitution of CD4Treg, CD4Tcon, and CD8 T cells was monitored for a 2-year period. CD3 T-cell counts gradually recovered to normal levels during this period but CD8 T cells recovered more rapidly than either CD4Tregs or CD4Tcons. Reconstituting CD4Tregs and CD4Tcons were predominantly central memory (CM) and effector memory (EM) cells and CD8 T cells were predominantly terminal EM cells. Thymic generation of naive CD4Tcon and CD8 T cells was maintained but thymic production of CD4Tregs was markedly decreased with little recovery during the 2-year study. T-cell proliferation was skewed in favor of CM and EM CD4Tcon and CD8 T cells, especially 6 to 12 months after HSCT. Intracellular expression of BCL2 was increased in CD4Tcon and CD8 T cells in the first 3 to 6 months after HSCT. Early recovery of naive and CM fractions within each T-cell population 3 months after transplant was also strongly correlated with the subsequent development of chronic graft-versus-host disease (GVHD). These dynamic imbalances favor the production, expansion, and persistence of effector T cells over CD4Tregs and were associated with the development of chronic GVHD.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2015        PMID: 26670634      PMCID: PMC4742552          DOI: 10.1182/blood-2015-10-672345

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Authors:  Kazuyuki Murase; Haesook T Kim; O R Gregory Bascug; Yutaka Kawano; Jeremy Ryan; Ken-ichi Matsuoka; Matthew S Davids; John Koreth; Vincent T Ho; Corey Cutler; Philippe Armand; Edwin P Alyea; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Anthony Letai; Jerome Ritz
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

2.  Reconstitution of regulatory T-cell subsets after allogeneic hematopoietic SCT.

Authors:  A Xhaard; H Moins-Teisserenc; M Busson; M Robin; P Ribaud; N Dhedin; S Abbes; M Carmagnat; V-D Kheav; G Maki; R Peffault de Latour; A Toubert; G Socié
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

Review 3.  The importance of regulatory T-cell heterogeneity in maintaining self-tolerance.

Authors:  Xiaomei Yuan; Guoyan Cheng; Thomas R Malek
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

Review 4.  Homeostatic control of regulatory T cell diversity.

Authors:  Adrian Liston; Daniel H D Gray
Journal:  Nat Rev Immunol       Date:  2014-01-31       Impact factor: 53.106

5.  Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.

Authors:  Simrit Parmar; Xiaoying Liu; Amer Najjar; Nina Shah; Hong Yang; Eric Yvon; Katy Rezvani; Ian McNiece; Patrick Zweidler-McKay; Leonard Miller; Steve Wolpe; Bruce R Blazar; Elizabeth J Shpall
Journal:  Blood       Date:  2014-11-26       Impact factor: 22.113

6.  Spatial map of human T cell compartmentalization and maintenance over decades of life.

Authors:  Joseph J C Thome; Naomi Yudanin; Yoshiaki Ohmura; Masaru Kubota; Boris Grinshpun; Taheri Sathaliyawala; Tomoaki Kato; Harvey Lerner; Yufeng Shen; Donna L Farber
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

7.  Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.

Authors:  M M Imanguli; E W Cowen; J Rose; S Dhamala; W Swaim; S Lafond; B Yagi; R E Gress; S Z Pavletic; F T Hakim
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

8.  Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Authors:  Alana A Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A Ramos; Robert A Krance; Kathryn Leung; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

9.  Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease.

Authors:  Shen Dong; Sylvie Maiella; Aliénor Xhaard; Yuanyu Pang; Lynn Wenandy; Jérome Larghero; Christophe Becavin; Arndt Benecke; Elisabetta Bianchi; Gérard Socié; Lars Rogge
Journal:  Blood       Date:  2013-07-01       Impact factor: 22.113

Review 10.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

View more
  77 in total

1.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

2.  Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.

Authors:  Jennifer S Whangbo; Haesook T Kim; Sarah Nikiforow; John Koreth; Ana C Alho; Bryn Falahee; Soomin Kim; Katharine Dusenbury; Marie J Fields; Carol G Reynolds; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood Adv       Date:  2019-04-09

Review 3.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

Review 4.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

5.  PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Authors:  Takeru Asano; Yusuke Meguri; Takanori Yoshioka; Yuriko Kishi; Miki Iwamoto; Makoto Nakamura; Yasuhisa Sando; Hideo Yagita; John Koreth; Haesook T Kim; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Yoshinobu Maeda; Mitsune Tanimoto; Jerome Ritz; Ken-Ichi Matsuoka
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

6.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.

Authors:  Reid W Merryman; Haesook T Kim; Pier Luigi Zinzani; Carmelo Carlo-Stella; Stephen M Ansell; Miguel-Angel Perales; Abraham Avigdor; Ahmad S Halwani; Roch Houot; Tony Marchand; Nathalie Dhedin; Willy Lescaut; Anne Thiebaut-Bertrand; Sylvie François; Aspasia Stamatoullas-Bastard; Pierre-Simon Rohrlich; Hélène Labussière Wallet; Luca Castagna; Armando Santoro; Veronika Bachanova; Scott C Bresler; Amitabh Srivastava; Harim Kim; Emily Pesek; Marie Chammas; Carol Reynolds; Vincent T Ho; Joseph H Antin; Jerome Ritz; Robert J Soiffer; Philippe Armand
Journal:  Blood       Date:  2017-01-10       Impact factor: 22.113

7.  Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Authors:  Yi-Bin Chen; Yvonne A Efebera; Laura Johnston; Edward D Ball; David Avigan; Lazaros J Lekakis; Carlos R Bachier; Paul Martin; Omar Duramad; Yasuyuki Ishii; Semi Han; Yu-Jin Jung; Dana Lee; Lori Kunkel; Robert S Negrin; Jack D Bui
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-16       Impact factor: 5.742

8.  In vivo kinetics and nonradioactive imaging of rapidly proliferating cells in graft-versus-host disease.

Authors:  Nataliya P Buxbaum; Donald E Farthing; Natella Maglakelidze; Martin Lizak; Hellmut Merkle; Andrea C Carpenter; Brittany U Oliver; Veena Kapoor; Ehydel Castro; Gregory A Swan; Liliane M Dos Santos; Nicolas J Bouladoux; Catherine V Bare; Francis A Flomerfelt; Michael A Eckhaus; William G Telford; Yasmine Belkaid; Remy J Bosselut; Ronald E Gress
Journal:  JCI Insight       Date:  2017-06-15

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

10.  SYK inhibitor entospletinib prevents ocular and skin GVHD in mice.

Authors:  Jonathan C Poe; Wei Jia; Julie A Di Paolo; Nancy J Reyes; Ji Yun Kim; Hsuan Su; John S Sundy; Adela R Cardones; Victor L Perez; Benny J Chen; Nelson J Chao; Diana M Cardona; Daniel R Saban; Stefanie Sarantopoulos
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.